Quick Answer
Core Scientific, Inc./tx reported Total Revenue of $319.02 million for fiscal year 2025.
Core Scientific, Inc./tx — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $319.02M -37.5% |
$510.67M +1.6% |
$502.40M -21.5% |
$640.31M +17.6% |
$544.48M +802.7% |
$60.32M |
| Net Income | -$288.62M +79.9% |
-$1.44B -483.3% |
-$246.49M +88.5% |
-$2.15B -4636.5% |
$47.31M +487.6% |
-$12.21M |
| Diluted EPS | -$0.88 +81.9% |
-$4.87 -649.2% |
-$0.65 +89.7% |
-$6.30 -3250.0% |
$0.20 +242.9% |
-$0.14 |
| Total Assets | $2.35B +59.1% |
$1.48B +107.3% |
$712.16M -11.8% |
$807.69M -66.9% |
$2.44B +16258993.3% |
$15.0K |
| Cash and Equivalents | $311.38M -62.8% |
$836.20M +1558.8% |
$50.41M +217.4% |
$15.88M -86.5% |
$117.87M | — |
| Stockholders Equity | -$962.74M -2.1% |
-$943.05M -58.0% |
-$596.94M -45.8% |
-$409.35M -130.5% |
$1.34B +1403.2% |
$89.22M -16.1% |
| R&D Expense | — | $11.83M +64.7% |
$7.18M -73.4% |
$26.96M +251.3% |
$7.67M +45.6% |
$5.27M |
| Operating Income | -$245.59M -72.9% |
-$142.06M -1685.4% |
$8.96M +100.4% |
-$2.11B -1704.3% |
$131.49M +2178.3% |
-$6.33M |
| Gross Profit | $37.90M -68.7% |
$121.07M -1.9% |
$123.46M +1369.8% |
$8.40M -96.5% |
$238.86M +2443.2% |
$9.39M |
| Shares Outstanding | 314.23M +7.4% |
292.61M -24.4% |
386.88M +3.1% |
375.23M +38.2% |
271.58M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $81.10M | -14.9% | +3.1% |
| Net Income | September 30, 2025 | -$146.66M | +67.8% | +84.3% |
| Diluted EPS | September 30, 2025 | -$0.46 | +60.7% | -1050.0% |
| Total Assets | September 30, 2025 | $2.30B | +149.1% | +16.1% |
| Cash and Equivalents | September 30, 2025 | $453.44M | +79.2% | -22.0% |
| Stockholders Equity | September 30, 2025 | -$1.13B | -54.6% | -5.9% |
| R&D Expense | September 30, 2024 | $2.84M | +26.1% | +30.7% |
| Operating Income | September 30, 2025 | -$57.42M | -39.3% | -118.5% |
| Gross Profit | September 30, 2025 | $3.90M | +2603.2% | -22.3% |
| Shares Outstanding | September 30, 2025 | 308.38M | +10.2% | +1.7% |
- Core Scientific, Inc./tx reported Total Revenue of $319.02 million for fiscal year 2025.
- Core Scientific, Inc./tx showed a decrease of -37.5% in Total Revenue compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Net Income of -$288.62 million for fiscal year 2025.
- Core Scientific, Inc./tx showed an increase of +79.9% in Net Income compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Diluted EPS of $0.88 per share (loss) for fiscal year 2025.
- Core Scientific, Inc./tx showed an increase of +81.9% in Diluted EPS compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Total Assets of $2.35 billion for fiscal year 2025.
- Core Scientific, Inc./tx showed an increase of +59.1% in Total Assets compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Cash and Equivalents of $311.38 million for fiscal year 2025.
- Core Scientific, Inc./tx showed a decrease of -62.8% in Cash and Equivalents compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Stockholders Equity of -$962.74 million for fiscal year 2025.
- Core Scientific, Inc./tx showed a decrease of -2.1% in Stockholders Equity compared to the prior fiscal year.
- Core Scientific, Inc./tx reported R&D Expense of $11.83 million for fiscal year 2024.
- Core Scientific, Inc./tx showed an increase of +64.7% in R&D Expense compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Operating Income of -$245.59 million for fiscal year 2025.
- Core Scientific, Inc./tx showed a decrease of -72.9% in Operating Income compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Gross Profit of $37.90 million for fiscal year 2025.
- Core Scientific, Inc./tx showed a decrease of -68.7% in Gross Profit compared to the prior fiscal year.
- Core Scientific, Inc./tx reported Shares Outstanding of 314.23 million shares for fiscal year 2025.
- Core Scientific, Inc./tx showed an increase of +7.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: